World generic giant Teva Pharmaceutical Industries is investing $1.0 million in tissue technology startup Cellcure Neurosciences, a stem cell therapy company focused on cures for Parkinson's disease and other neurodegenerative disorders, according to Israel's Haaretz.com.
The investment prices Cellcure at $13.0 million, said Israel's Hadasit Bio-Holdings, which also owns a stake in the firm. One of Teva's two innovative drugs, Azilect (rasagiline), is a treatment for PD. The agent earned $28.0 million in second-quarter 2007 (Marketletter August 20).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze